THE QUALITY PARADIGM FOR DRUG EXCIPIENTS
This article was originally published in The Gold Sheet
...needs to be refocused onto their composition and away from the impurities orientation in the API arena, the International Pharmaceutical Excipients Council is urging. Clearer definition of excipient components, mixtures and additives is viewed as critical to more effective communication between suppliers, drug manufacturers and regulators, and IPEC is working on a guideline to help build the foundation for compendial realignment and harmonization accordingly. Meanwhile, dosage manufacturers are tightening their excipient control systems and looking at new analytical technologies to meet the quality by design challenge.
You may also be interested in...
Drug manufacturers are adopting QbD but there are exceptions, especially among some generics firms, McKinsey finds in industry survey. The top challenge to further adoption: misalignment between R&D and commercial operations. Second is a lack of belief in the business case. However, the cost turns out to be low and the financial reward high, McKinsey says.
Using QbD to set specs that make a difference to patients is hard but important work, FDA's Woodcock says. Prasugrel, levothyroxine, pallodone examples explored. How to establish a 'work space.' How to make the right correlations.
As biotech firms begin to pilot QbD they wrestle with FDA over non-critical process parameters, postapproval changes and more. They are exploring how to define design spaces, change them, identify their edges. And they're still wondering what regulatory relief they might get in return for investing in quality-by-design studies.